Idarubicin combined chemotherapy regimen for 22 cases with refractory or relapsed multiple myeloma / 中国癌症杂志
China Oncology
;
(12)1998.
Article
in Chinese
| WPRIM
| ID: wpr-536601
ABSTRACT
Purpose:
To study the efficacy and toxicity of VIDM regimen (vincristine,idarubicin,dexamethasone and melphalan) for refractory or relapsed multiple myeloma(MM).Methods:
45 refractory or relapsed MM patients were randomized into two groups VIDM group(treatment group) had 22 patients treated with VIDM regimen, VAD group(control group) had 23 patients with VAD regimen.Results:
The effective rate with VIDM regimen (59.1%) was significantly higher than that of VAD regimen (26.1%) (P
Full text:
Available
Index:
WPRIM (Western Pacific)
Type of study:
Controlled clinical trial
Language:
Chinese
Journal:
China Oncology
Year:
1998
Type:
Article
Similar
MEDLINE
...
LILACS
LIS